

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Obeticholic acid for treating primary biliary cirrhosis [ID785]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Intercept Pharmaceuticals (obeticholic acid) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • Black Health Agency • British Liver Trust • Liver4Life • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • The PBC Foundation <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for the Study of the Liver • British Geriatrics Society • British Liver Nurses Forum • British Society of Gastroenterology • CORE – Digestive Disorders Foundation • ESPRIT • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Herts Valleys CCG (West) 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Association of Gastroenterology and Endoscopy (WAGE) <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AAH Pharmaceuticals (bezafibrate, ciprofibrate, gemfibrozil) • Actavis UK (bezafibrate, • Alliance Healthcare (bezafibrate, ciprofibrate, ,gemfibrozil) • DE Pharmaceuticals (bezafibrate, ciprofibrate, gemfibrozil) • Dr Falk Pharma UK (ursodeoxycholic acid) • Mawdsley Brooks & Company (bezafibrate, gemfibrozil) • Mylan (bezafibrate) • Norgine (ursodeoxycholic acid) • Pfizer (gemfibrozil) • Phoenix Healthcare Distribution (bezafibrate, ciprofibrate, gemfibrozil) • Primegen (ciprofibrate)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS North Norfolk CCG • Welsh Government 	<ul style="list-style-type: none"> • Sandoz (bezafibrate) • Sigma Pharmaceuticals (bezafibrate, ciprofibrate, gemfibrozil) • Teva UK (bezafibrate, gemfibrozil) • Tillomed Laboratories (gemfibrozil) • Waymade Healthcare (bezafibrate, gemfibrozil) • Wockhardt UK (ursodeoxycholic acid) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that markets comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.